BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

At APIC New Comparative Effectiveness Research Study Shows RyMed Technologies's InVision-Plus® Intraluminal Protection System Dramatically Reduced Catheter-Related Bloodstream Infections


7/11/2011 10:53:13 AM

FRANKLIN, Tenn., July 11, 2011 /PRNewswire/ -- Denise Macklin, BSN, RNC, representing the research team ofDr. Cynthia C. Chernecky Ph.D., RN, AOCN, FAAN, Dr. Jennifer Waller, Ph.D., both from Georgia Health Sciences University; and Dr. William Jarvis M.D., Jason & Jarvis Associates, exhibited a poster at the recent APIC 2011 (Association for Professionals in Infection Control and Epidemiology) conference in Baltimore, titled "Clinical Comparisons of Split Septum, Positive and Negative Mechanical Valve Intravenous Connectors to an Intraluminal Protection Connector on Infection Rates." This comparative effectiveness study shows the success of RyMed Technologies' InVision-Plus® Intraluminal Protection System (www.rymedtech.com) versus all IV connector classes including split septum, negative and positive. The APIC is the largest annual gathering of infection preventionists in the world.

As part of the national health care reform debate, the National Institutes of Health (NIH) uses Comparative Effectiveness Research (CER)to rigorously evaluate the impact of different options, treatments or approaches to a given condition or problem. The goal of CER is to improve outcomes by developing and communicating evidence-based information to the health care community, including patients, providers and decision-makers about the effectiveness of various treatments compared to others. This study method is strengthened when a large random sample is used and one change in practice is made. This study included over 122,000 catheter days of aggregate data from 8 states including all U.S. demographic regions and different clinical settings including ICU, SICU, house-wide, inpatient oncology and long-term acute care. Participants in the study reported that a combined 128 infections were prevented according to the data collected, amounting to approximately $6.2 million in savings based on accepted infection costs. These institutions had similar care and maintenance practices in place.

The conclusion of the study supports other published research that shows a significantly higher bloodstream infection (BSI) rate when split septum, negative or positive pressure mechanical valve intravenous connectors were used. However, this study goes on to show a dramatic decrease in BSI when the InVision-Plus® Intraluminal Protection System is instead used. BSIs can cause treatment delays, add time to nursing care, increase costs, increase mortality and decrease quality of life for the patient and family.

"Considering each infection costs hospitals an average of $35,000, this study should be an eye-opener for the healthcare industry as infection prevention and cost savings are so important," said Dr. Chernecky. "We believe this study is the first multi-center CER study that includes IV connectors from all luer-activated classes since Dr. Jarvis published his 2009 article in Clinical Infectious Diseases on Hospital Acquired Infections (HAI) associated with both negative and positive displacement connectors."

"This study is highly important because is corroborates significant clinical findings of decreased infection rates to other in-vitro findings made from previous studies on the InVision-Plus®," said Dana Wm. Ryan, President & CEO, RyMed Technologies, Inc. "It shows that design features matter and simply changing to the InVision-Plus® allows for a very positive outcome."

Catheter-related bloodstream infection (CR-BSI) continues to be one of the most frequent hospital acquired infections (HAIs) reported by hospitals nationwide. It has been reported that a patient that develops a CR-BSI could die up to 25% of the time. As a result, it is logical to conclude that by reducing CR-BSIs, RyMed's InVision-Plus® technology with zero fluid displacement saves lives and reduces cost.

About RyMed Technologies, Inc.

Founded in 1994, RyMed Technologies specializes in the development and marketing of innovative safety products in the field of intravenous catheter care management. The company's products are designed to help reduce CR-BSIs and intraluminal thrombotic catheter occlusions associated with needleless IV connectors. More than 10 years of research and development have gone into InVision-Plus® IV Connector. In January, 2011 the Company introduced the first chlorhexidine/silver ion technology with the new InVision-Plus® CS. For more information, call (615) 790-8093 or access www.rymedtech.com.

SOURCE RyMed Technologies



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES